NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
02/21/2026
Back to search
Official data from USPTO
OBI PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
03/17/2026
Trademark type
Combined
Nice classes
5
Filing date
07/18/2013
Registration date
05/19/2015
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/21/2026
Last transaction
03/17/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
3
Owner type
03
Owner location
Taipei City, TW
Examiner
WIENER, MICHAEL
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the letters "OBI", with the letter "O" in teal and light teal and in the form of a spinning wheel, with the letters "BI" in teal. Beneath these letters is a curved line in teal. Beneath the curved line is the term "PHARMA" in teal.
Holders and representatives
Holders
OBI PHARMA, INC.
OBI PHARMA, INC.
Representatives
Michael T. Smith Birch, Stewart, Kolasch & Birch, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Antibiotic preparations; Antibiotics; Anti-cancer preparations; Anti-infectives; Anti-inflammatories; Biological preparations for the treatment of cancer; Chemical reagents for medical or veterinary purposes; Diagnostic agentspreparations and substances for medical purposes; Diagnostic kits consisting primarily of monoclonal antibodiesbuffers and reagents for use in disease testing; Diagnostic preparations for medical and veterinary use; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations for medical purposes for detecting the presence of malignantinflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic preparations for medical purposes; Diagnostic radiopharmaceutical preparations; Diagnostic reagents for medical use; Diagnostic reagents and contrast media for medical use; Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; Gastro-intestinal treatment preparations; In-vivo diagnostic agent used for detection and monitoring of angiogenesis and anti-angiogenic therapy; Medical diagnostic reagents and assays for testing body fluids; Medical diagnostic reagents and assays for testing body fluids for microorganisms; Medical diagnostic reagents for the analysis of body fluids; Medicinal preparations for the treatment of infectious diseases and for using in oncology; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesfor the treatment of bacteria-based diseasesfor the treatment of diabetesanti - infective preparationsantiviral preparationsantibioticsantifungal preparations and vaccines; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Reagents and media for medical and veterinary diagnostic purposes; Reagents for medical use; Vaccine adjuvants; Vaccine preparations; Vaccine stabilizers; Vaccines
Publications
History of USPTO decisions and trademark events.
50 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
02/21/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
02/21/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/19/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
11/19/2025
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
05/19/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/27/2024
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
03/27/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/27/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/27/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/27/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/27/2024
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
04/02/2022
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
04/02/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/02/2022
ES8R
TEAS SECTION 8 RECEIVED
09/24/2021
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
05/19/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/02/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
05/19/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/03/2015
PUBO
PUBLISHED FOR OPPOSITION
03/03/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/11/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/26/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/20/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/15/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/15/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/15/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/16/2014
GNRT
NON-FINAL ACTION E-MAILED
07/16/2014
CNRT
NON-FINAL ACTION WRITTEN
07/16/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/09/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/09/2014
ALIE
ASSIGNED TO LIE
07/04/2014
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/25/2014
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/21/2014
GNSL
LETTER OF SUSPENSION E-MAILED
03/21/2014
CNSL
SUSPENSION LETTER WRITTEN
03/21/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/21/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/20/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/20/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/06/2013
GNRT
NON-FINAL ACTION E-MAILED
11/06/2013
CNRT
NON-FINAL ACTION WRITTEN
11/06/2013
DOCK
ASSIGNED TO EXAMINER
10/31/2013
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
08/07/2013
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
08/07/2013
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
08/06/2013
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
07/25/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/24/2013
NWAP
NEW APPLICATION ENTERED
07/22/2013
Continuous trademark protection
Get notified about every new filing that threatens OBI PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.